Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a study medicine called MK-1045 in adults with systemic lupus erythematosus SLE or rheumatoid arthritis RA. This phase 1 clinical trial aims to learn about the safety and how well people tolerate MK-1045 when given at different dose levels. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment outcomes for these autoimmune conditions. Participants will receive MK-1045 through intravenous IV infusion in varying ways depending on their study group. Some will get a single IV dose at different dose levels, while others will receive three step-up doses over a 3-week interval, progressing from a prime dose to a target dose. The study includes dose escalation panels and an optional dose expansion phase for further evaluation. During the study, participants will be monitored for adverse events up to 52 weeks. Researchers will assess the number of participants experiencing side effects or discontinuing the drug due to side effects. Blood tests will measure MK-1045 levels and the effect on peripheral B cell counts at specific times. This detailed monitoring helps understand the drugs safety, pharmacokinetics, and pharmacodynamics throughout the trial duration.
Actively Recruiting
Study of a Flavonoid-rich Mediterranean Diet to Support People with Multiple Sclerosis Aged 30 to 65
Researchers are evaluating the effects of a flavonoid-rich Mediterranean diet on individuals with multiple sclerosis MS, a condition influenced by environmental factors like nutrition. This study aims to understand how this specialized diet might impact disease parameters in people living with MS. Participants will follow a set of dietary guidelines focusing on consuming foods rich in flavonoids as part of an adjusted Mediterranean diet. The study includes three key assessment timepoints before starting the strict diet, after completing the diet, and following a three-month follow-up period. During the study, researchers will monitor changes in the participants gut microbiota at these three intervals. The total study duration includes initial diet adherence and a follow-up phase to evaluate lasting effects. Participants will be regularly assessed to track how the diet influences their condition over time.
Actively Recruiting
Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.
Actively Recruiting
Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are evaluating LY4005130, an intravenous drug, to see how well it is tolerated and what side effects may occur in adults with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled study compares LY4005130 to a placebo over about 48 weeks, including screening. Participants must have NSV diagnosed for at least 3 months with specific body surface area involvement. Participants receive either LY4005130 or placebo intravenously during the treatment period. The study includes a 24-week treatment phase where the drug or placebo is administered, and blood tests are done to understand how the body processes the drug and how it affects the skin condition. The study drug is given through the vein in the arm. During the study, participants will have assessments including blood tests, skin evaluations using Vitiligo Area Scoring Indexes F-VASI and T-VASI, and skin biopsies to measure gene expression changes. Researchers will monitor safety, drug levels in the blood, and treatment effects up to 48 weeks. The main outcome is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.
Actively Recruiting
Healthy Volunteer
Researchers are investigating how different levels of fatigue during power training affect strength, movement, and muscle function in healthy older adults aged 65 to 85 years. This study aims to understand how fatigue influences recovery, muscle soreness, and perceived exercise difficulty. The goal is to find safer and more effective ways to improve strength, power, and mobility through power training. Participants will complete three supervised power-training sessions using a pneumatic leg press machine. Each session involves four sets of exercises under varying fatigue conditions stopping when movement speed decreases by 10% low fatigue, stopping at 30% speed decrease moderate fatigue, or performing cluster sets at 10% speed loss with total work matched to the moderate fatigue session. Sessions occur about one week apart. During each session, movement speed is monitored continuously. Researchers will assess muscle strength and function before, immediately after, and 24 hours post-exercise. Participants will provide small blood samples, report muscle soreness for two days after exercise, and rate how hard the exercise feels. The study measures various outcomes including muscle activity, oxygenation, blood lactate, and functional performance tests to evaluate the effects of different fatigue levels on older adults power training response.
Actively Recruiting
Healthy Volunteer
Multiple sclerosis MS is a chronic disease affecting the central nervous system that often causes walking difficulties, balance problems, fatigue, cognitive challenges, and higher fall risk even in early stages. Standard walking tests may not fully capture these issues because they mainly measure speed or distance, missing the complex adaptations needed for safe walking in everyday life. This research aims to better understand how people with MS adjust their walking in response to changing environments by studying both anticipatory and reactive gait adaptations and their brain activity. The study includes 16 people with MS and 16 healthy adults matched by age and sex. Participants undergo a single testing session where various motor performance tests and questionnaires assess walking, balance, fatigue, and cognitive function. Proactive gait adaptability is tested by having participants walk on a 10-meter path with stepping targets at varying difficulty levels. Reactive gait adaptability is measured using a treadmill system that applies unexpected disturbances while tracking detailed movement and brain blood flow using special sensors. Participants will complete physical tests like the Timed 25-Foot Walk and 6-Minute Walk Test, along with cognitive assessments and balance evaluations. Researchers will record responses to gait challenges and brain oxygen levels during these tasks. The main measures include performance on the Walking Adaptability Ladder Test and reactive gait changes during treadmill perturbations. This comprehensive approach aims to reveal new insights into walking adaptations in MS, supporting improved outcome measures and rehabilitation strategies. The study is expected to run until late 2026.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two multi-component dietary interventions aimed at promoting healthy and sustainable eating habits and preventing weight gain among Flemish higher education students. This study focuses on supporting students during the transition from secondary school to higher education, a period when unhealthy eating and weight gain are common. The interventions are part of a collaboration involving several research groups and the Flemish Institute for Healthy Living, with the goal of encouraging healthier lifestyle choices to reduce cancer risk. The interventions last for eight weeks and are implemented at a university and a college campus. They include social media campaigns on Instagram, behavioral nudges in student cafeterias to encourage healthier food choices, and interactive workshops that teach practical skills such as reading nutrition labels. Physical changes in dining areas and information stands on campus also support awareness and behavior change. Two other campuses serve as control groups with no intervention. Sales data of healthy food options will also be monitored during the intervention period. Participants will complete questionnaires before the intervention, immediately after, and five months later to measure changes in nutrition behavior, attitude, knowledge, self-efficacy, perceived food environment, intentions, barriers, cooking skills, weight, and height. A process evaluation involving focus groups and questionnaires will assess how the interventions are implemented and experienced. The study runs from February to December 2025 and aims to provide insights that could lead to scaling up the program for broader cancer prevention efforts.
Actively Recruiting
Healthy Volunteer
Walking and motor control difficulties are common in people with multiple sclerosis pwMS, even in those with mild disability. Early changes in walking can signal disease progression, but current tests mainly measure time or distance and may miss subtle changes. This research focuses on better ways to assess walking adaptability, which involves adjusting walking patterns in response to challenges like fatigue and balance. The study aims to evaluate two tests, the Walking Adaptability Ladder Test WALT and the Foot Tap Test FTT, in pwMS with mild disability to see how reliable and valid they are. The study will include 50 people with multiple sclerosis and 50 healthy controls matched by age and sex. Participants will complete the WALT, FTT, Balance Recovery Scale, and Gait-Specific Attention Profile twice, one week apart, to test reliability. Additional walking and motor function tests will be performed, including the Timed 25-Foot Walk and the 6-Minute Walk Test. Cognitive processing speed and patient-reported outcomes about walking limitations, fatigue, balance confidence, and fall concerns will also be collected. Data will be gathered in Spain, Italy, and Belgium, with retests performed in Spain. Participants will be assessed through various motor and walking tests, questionnaires, and wearable sensors to record movement. The study will analyze the consistency and accuracy of these tests and compare performance between pwMS and healthy controls. The main measurements are the WALT and FTT performed on two separate days. The research will help identify which tests best detect subtle walking impairments and how clinical test results relate to patients self-reported experiences. The study participation spans the test days and follow-up for reliability testing.
1-10 of 17
1